Advertisement

A fatty liver leads to a broken heart?

  • Leon A. Adams
    Correspondence
    Corresponding authors. Addresses: School of Medicine and Pharmacology, UWA, QEII Medical Campus, Verdun St, Nedlands, WA 6009, Australia. Tel.: +61 8 6151 1052; fax: +61 8 6151 1028 (L. Adams), or Institute of Cellular Medicine, The Medical School, Newcastle University, 4th Floor, William Leech Building, Framlington Place, Newcastle-upon-Tyne NE2 4HH, UK. Tel.: +44 (0) 191 208 7012; fax: +44 (0) 191 208 0723.
    Affiliations
    School of Medicine and Pharmacology, The University of Western Australia, Nedlands, Australia
    Search for articles by this author
  • Quentin M. Anstee
    Correspondence
    Corresponding authors. Addresses: School of Medicine and Pharmacology, UWA, QEII Medical Campus, Verdun St, Nedlands, WA 6009, Australia. Tel.: +61 8 6151 1052; fax: +61 8 6151 1028 (L. Adams), or Institute of Cellular Medicine, The Medical School, Newcastle University, 4th Floor, William Leech Building, Framlington Place, Newcastle-upon-Tyne NE2 4HH, UK. Tel.: +44 (0) 191 208 7012; fax: +44 (0) 191 208 0723.
    Affiliations
    Liver Research Group, Institute of Cellular Medicine, The Medical School, Newcastle University, Framlington Place, Newcastle-upon-Tyne, UK
    Search for articles by this author
Published:March 26, 2016DOI:https://doi.org/10.1016/j.jhep.2016.03.012
      Non-alcoholic fatty liver disease (NAFLD) typically exists in a milieu of disturbed metabolism, including increased total body adiposity, insulin resistance, impaired glucose tolerance and dyslipidemia [
      • Anstee Q.M.
      • Targher G.
      • Day C.P.
      Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis.
      ]. Cumulatively, these factors increase the risk for cardiovascular disease (CVD), and so it is not surprising that CVD is the leading cause of death in NAFLD patients [
      • Adams L.A.
      • Lymp J.F.
      • St Sauver J.
      • Sanderson S.O.
      • Lindor K.D.
      • Feldstein A.
      • et al.
      The natural history of nonalcoholic fatty liver disease: a population-based cohort study.
      ]. The challenge over the past decade has been to tease apart the complex and inter-dependent relationships between NAFLD and these etiological factors, to establish whether NAFLD per se increases the risk of developing CVD. The validation of NAFLD as a significant additional risk factor would have direct relevance for primary preventative strategies against CVD.

      Abbreviations:

      NAFLD (non-alcoholic fatty liver disease), CVD (cardiovascular disease), cIMT (carotid intimal media thickness), FLI (fatty liver index), GGT (gamma-glutamyl transferase)

      Keywords

      Linked Article

      • Fatty liver is an independent predictor of early carotid atherosclerosis
        Journal of HepatologyVol. 65Issue 1
        • Preview
          Non-alcoholic fatty liver disease (NAFLD) is an increasingly common condition seen in patients with obesity, type 2 diabetes, atherogenic dyslipidemia and arterial hypertension. The leading cause of death in patients with NAFLD is cardiovascular mortality, which is not surprising given the high prevalence of the above-mentioned cardiometabolic risk factors [1,2]. However, a large body of data indicates that the fatty and inflamed liver expresses several pro-inflammatory and procoagulant factors, as well as genes involved in accelerated atherogenesis [3,4].
        • Full-Text
        • PDF
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Hepatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Anstee Q.M.
        • Targher G.
        • Day C.P.
        Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis.
        Nat Rev Gastroenterol Hepatol. 2013; 10: 330-344
        • Adams L.A.
        • Lymp J.F.
        • St Sauver J.
        • Sanderson S.O.
        • Lindor K.D.
        • Feldstein A.
        • et al.
        The natural history of nonalcoholic fatty liver disease: a population-based cohort study.
        Gastroenterology. 2005; 129: 113-121
        • Pais R.
        • Giral P.
        • Khan J.-F.
        • Rosenbaum D.
        • Housset C.
        • Poynard T.
        • et al.
        Fatty liver as an independent predictor of early carotid atherosclerosis: results from a large transversal and long-term follow-up.
        J Hepatol. 2016; 65: 95-102
        • Lorenz M.W.
        • Markus H.S.
        • Bots M.L.
        • Rosvall M.
        • Sitzer M.
        Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis.
        Circulation. 2007; 115: 459-467
        • Bedogni G.
        • Bellentani S.
        • Miglioli L.
        • Masutti F.
        • Passalacqua M.
        • Castiglione A.
        • et al.
        The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population.
        BMC Gastroenterol. 2006; 6: 33
        • Cuthbertson D.J.
        • Weickert M.O.
        • Lythgoe D.
        • Sprung V.S.
        • Dobson R.
        • Shoajee-Moradie F.
        • et al.
        External validation of the fatty liver index and lipid accumulation product indices, using 1H-magnetic resonance spectroscopy, to identify hepatic steatosis in healthy controls and obese, insulin-resistant individuals.
        Eur J Endocrinol. 2014; 171: 561-569
        • Long M.T.
        • Wang N.
        • Larson M.G.
        • Mitchell G.F.
        • Palmisano J.
        • Vasan R.S.
        • et al.
        Nonalcoholic fatty liver disease and vascular function: cross-sectional analysis in the Framingham heart study.
        Arterioscler Thromb Vasc Biol. 2015; 35: 1284-1291
        • Huang R.C.
        • Beilin L.J.
        • Ayonrinde O.
        • Mori T.A.
        • Olynyk J.K.
        • Burrows S.
        • et al.
        Importance of cardiometabolic risk factors in the association between nonalcoholic fatty liver disease and arterial stiffness in adolescents.
        Hepatology. 2013; 58: 1306-1314
        • VanWagner L.B.
        • Wilcox J.E.
        • Colangelo L.A.
        • Lloyd-Jones D.M.
        • Carr J.J.
        • Lima J.A.
        • et al.
        Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: A population-based study.
        Hepatology. 2015; 62: 773-783
        • Oni E.T.
        • Agatston A.S.
        • Blaha M.J.
        • Fialkow J.
        • Cury R.
        • Sposito A.
        • et al.
        A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?.
        Atherosclerosis. 2013; 230: 258-267
        • Fabbrini E.
        • Yoshino J.
        • Yoshino M.
        • Magkos F.
        • Tiemann Luecking C.
        • Samovski D.
        • et al.
        Metabolically normal obese people are protected from adverse effects following weight gain.
        J Clin Invest. 2015; 125: 787-795
        • Vanni E.
        • Marengo A.
        • Mezzabotta L.
        • Bugianesi E.
        Systemic complications of nonalcoholic fatty liver disease: when the liver is not an innocent bystander.
        Semin Liver Dis. 2015; 35: 236-249
        • Kim D.
        • Kim W.R.
        • Kim H.J.
        • Therneau T.M.
        Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States.
        Hepatology. 2013; 57: 1357-1365
        • Targher G.
        • Bertolini L.
        • Poli F.
        • Rodella S.
        • Scala L.
        • Tessari R.
        • et al.
        Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients.
        Diabetes. 2005; 54: 3541-3546
        • Haring R.
        • Wallaschofski H.
        • Nauck M.
        • Dorr M.
        • Baumeister S.E.
        • Volzke H.
        Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels.
        Hepatology. 2009; 50: 1403-1411
        • Hamaguchi M.
        • Kojima T.
        • Takeda N.
        • Nagata C.
        • Takeda J.
        • Sarui H.
        • et al.
        Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease.
        World J Gastroenterol. 2007; 13: 1579-1584
        • Pisto P.
        • Santaniemi M.
        • Bloigu R.
        • Ukkola O.
        • Kesaniemi Y.A.
        Fatty liver predicts the risk for cardiovascular events in middle-aged population: a population-based cohort study.
        BMJ Open. 2014; 4e004973
        • Liu Y.L.
        • Reeves H.L.
        • Burt A.D.
        • Tiniakos D.
        • McPherson S.
        • Leathart J.B.
        • et al.
        TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease.
        Nat Commun. 2014; 5: 4309
        • Holmen O.L.
        • Zhang H.
        • Fan Y.
        • Hovelson D.H.
        • Schmidt E.M.
        • Zhou W.
        • et al.
        Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk.
        Nat Genet. 2014; 46: 345-351
        • Dongiovanni P.
        • Petta S.
        • Maglio C.
        • Fracanzani A.L.
        • Pipitone R.
        • Mozzi E.
        • et al.
        Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease.
        Hepatology. 2015; 61: 506-514
        • Kahali B.
        • Liu Y.L.
        • Daly A.K.
        • Day C.P.
        • Anstee Q.M.
        • Speliotes E.K.
        TM6SF2: catch-22 in the fight against nonalcoholic fatty liver disease and cardiovascular disease?.
        Gastroenterology. 2015; 148: 679-684
        • Anstee Q.M.
        • Seth D.
        • Day C.P.
        Genetic factors that affect risk of alcoholic and non-alcoholic fatty liver disease.
        Gastroenterology. 2016; (Feb 9. pii: S0016-5085(16)00138-4; [Epub ahead of print])https://doi.org/10.1053/j.gastro.2016.01.037
        • Zhao D.
        • Liu J.
        • Xie W.
        • Qi Y.
        Cardiovascular risk assessment: a global perspective.
        Nat Rev Cardiol. 2015; 12: 301-311
        • Treeprasertsuk S.
        • Leverage S.
        • Adams L.A.
        • Lindor K.D.
        • St Sauver J.
        • Angulo P.
        The Framingham risk score and heart disease in nonalcoholic fatty liver disease.
        Liver Int. 2012; 32: 945-950
        • Corey K.E.
        • Vuppalanchi R.
        • Wilson L.A.
        • Cummings O.W.
        • Chalasani N.
        NASH resolution is associated with improvements in HDL and triglyceride levels but not improvement in LDL or non-HDL-C levels.
        Aliment Pharmacol Ther. 2015; 41: 301-309